42 Atopic Dermatitis Clinical Trials in Dallas, TX (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Atopic Dermatitis Studies in Dallas

NCT00992303Recruiting

Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting tissue s...

Dallas, TX10,000 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05646485Recruiting

Bladder Cancer Screening Trial

There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help asses...

Dallas, TXNA1,000 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT04739072Recruiting

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors...

Dallas, TX1,000 participantsM.D. Anderson Cancer Center

View Study Details

NCT06764771Recruiting

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tum...

Dallas, TXPHASE1437 participantsBristol-Myers Squibb

View Study Details

NCT05941507Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expa...

Dallas, TXPHASE1300 participantsLigaChem Biosciences, Inc.

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

Dallas, TXPHASE1248 participantsBioNTech SE

View Study Details

NCT06476808Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors....

Dallas, TXPHASE1240 participantsBristol-Myers Squibb

View Study Details

NCT07175441Recruiting

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic gua...

Dallas, TXPHASE2220 participantsRiboscience, LLC.

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

Dallas, TXPHASE1216 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT07643766Recruiting

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose level...

Dallas, TXPHASE2200 participantsEnveda Therapeutics

View Study Details

NCT07604571Recruiting

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients ...

Dallas, TXPHASE1194 participantsNovartis Pharmaceuticals

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Dallas, TXPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT07635095Recruiting

A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

The goal of this clinical trial is to compare two different presentations (vial and syringe versus autoinjector) of navenibart in healthy adult volunteers. The main questions it aims to answer are: *...

Dallas, TXPHASE1180 participantsAstria Therapeutics, Inc.

View Study Details

NCT06108050Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combin...

Dallas, TXPHASE1177 participantsJazz Pharmaceuticals

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

Dallas, TXPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT07605962Recruiting

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle....

Dallas, TXPHASE1140 participantsUnited Immunity, co., Ltd.

View Study Details

NCT06974110Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Dallas, TXPHASE1132 participantsMOMA Therapeutics

View Study Details

NCT05394103Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

Dallas, TXPHASE1130 participantsQurient Co., Ltd.

View Study Details

NCT05576974Recruiting

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent....

Dallas, TXPHASE2120 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06028074Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clini...

Dallas, TXPHASE1111 participantsGeorgiamune Inc

View Study Details

NCT07148128Recruiting

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours....

Dallas, TXPHASE1110 participantsAuricula Biosciences Inc.

View Study Details

NCT05490472Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....

Dallas, TXPHASE1102 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Dallas, TXPHASE1100 participantsAlyssum Therapeutics

View Study Details

NCT05725291Recruiting

AMT-116 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immuno...

Dallas, TXPHASE180 participantsMultitude Therapeutics Inc.

View Study Details

NCT06477692Recruiting

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)...

Dallas, TXPHASE280 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05892718Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what ...

Dallas, TXPHASE180 participantsFBD Biologics Limited

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Dallas, TXPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT05269316Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors...

Dallas, TXPHASE161 participantsImpact Therapeutics, Inc.

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Dallas, TXPHASE160 participantsKaliVir Immunotherapeutics

View Study Details

NCT04196257Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or ma...

Dallas, TXPHASE150 participantsBio-Path Holdings, Inc.

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Dallas, TXPHASE149 participantsLaNova Medicines Limited

View Study Details

NCT06982352Recruiting

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solu...

Dallas, TXPHASE148 participantsLAPIX Therapeutics Inc.

View Study Details

NCT06415487Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expre...

Dallas, TXPHASE130 participantsAcepodia Biotech, Inc.

View Study Details

NCT05023018Recruiting

NEO100 and High-Grade Meningioma

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patie...

Dallas, TXPHASE230 participantsNeonc Technologies, Inc.

View Study Details

NCT06673017Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naï...

Dallas, TXPHASE126 participantsPanTher Therapeutics

View Study Details

NCT03067467Recruiting

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \[1-13C\]pyruvate MRSI....

Dallas, TX25 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT04926467Recruiting

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with...

Dallas, TXPHASE224 participantsBaylor Research Institute

View Study Details

NCT05239624Recruiting

Enfortumab Vedotin and Pembrolizumab in People with Bladder Cancer

This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to h...

Dallas, TXPHASE223 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07405645Recruiting

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

This phase 1 multi-site study investigates the safety and initial effectiveness of focused ultrasound lesioning of the contralateral mesencephalon for severe, opioid-resistant pain associated with hea...

Dallas, TXNA20 participantsUniversity of Virginia

View Study Details

NCT06044857Recruiting

PSMA PET Response Guided SabR in High Risk Pca

Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Il...

Dallas, TXPHASE120 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06394570Recruiting

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

STAR-EV will evaluate the combination of enfortumab vedotin plus radiotherapy (RT) as neoadjuvant treatment for muscle invasive bladder cancer prior to radical cystectomy surgery. The study will use "...

Dallas, TXPHASE119 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05936619Recruiting

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of...

Dallas, TXNA2 participantsNader Pouratian

View Study Details

About Atopic Dermatitis Clinical Trials in Dallas

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 42 atopic dermatitis clinical trials recruiting participants in Dallas, TX. These studies are seeking a combined 16,490 participants. Research is being sponsored by University of Texas Southwestern Medical Center, M.D. Anderson Cancer Center, Bristol-Myers Squibb and 32 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Dallas — FAQ

Are there atopic dermatitis clinical trials in Dallas?

Yes, there are 42 atopic dermatitis clinical trials currently recruiting in Dallas, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 42 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 12, 2026 from ClinicalTrials.gov